Clinical Trials Browser

Phase 2 × Recurrent Uterine Corpus Carcinoma × Clear all

NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

Recurrent Uterine Corpus Carcinoma

NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

Phase 2 Unknown

67 enrolled 9 charts

Recurrent Uterine Corpus Carcinoma